RE:RE:RE:When you compareSo you discount Stagezero's Covid revenue but not Exas both of which had y/y increase over 20%. Stage diversifies and now has over $1 million per quarter from Care and it's growing but hey why not disregard that too. Revenue is revenue.
Can't fix stupid here.
The market cap will increase with revenues over the next few quarters. They don't report Q1 until May 16 so not having this arguement daily until than. I'm comfortable knowing revenues are increasing.
If you can't see the company has taken strides to grow multiple revenue streams and that the market cap at only 3x revenues is way undervalued than you truly are just bashing for the sake of bashing. Yes they have a loss as do Billion dollar companies. This is about revenue growth and despite the roll out taking over a year revenues are increasing with AVRT, TREAT and ARISTOTLE in the US, Canada, UK and Europe. All adding to revenue growth and the bottom line.
So wait on the sidelines or buy and hold but the SP will be increasing with more revenues.
Your lack of business acumen is telling.
4real4ever wrote: The only thing you forget to say is that SZLS have no revenue since 5 years from Cancer testing. The only increasing revenues was due to Covid testing only and they not increasing but go down. Without Covid SZLS will be in BK right now
EXAS sale huge numbers of tests since many years. Peoples and the industry want their products
LithLover wrote: So even you make the point with EXAS that it's all about revenues, revenue growth over last year at 29% and despite EXAS showing a net loss they still have a market cap of 10-15 times revenues.
Stagezero has annual revenues of $5 million (and increasing), 22% growth over last year and a market cap of only 3 times revenues.
Thanks for making the same point we are that wiith the contuinued revenue growth SZLS is under valued at this level.
4real4ever wrote: Exact Sciences Announces Fourth Quarter 2021 Results
02/22/2022
- Total fourth quarter revenue of $474M, including Screening revenue of $278M, Precision Oncology revenue of $149M, and COVID-19 testing revenue of $47M
- Total 2021 revenue, excluding COVID-19 testing, increased 29% compared to 2020, including 30% increase in Screening revenue and 28% increase in Precision Oncology revenue
- Screening revenue growth driven by Cologuard rescreens, Cologuard use in 45-49 age group, expansion of primary care sales team, and increased in-person sales calls
That's a real company and why their share price is $73 usd
Nailoser and friends you put your money in the wrong one
